TL;DR: The Centers for Medicare & Medicaid Services modified NCD 135, reaffirming that vitamin B12 injections to strengthen tendons, ligaments, and related foot structures are not covered under Medicare, effective March 7, 2026. Here's what billing teams need to know.
This is a non-coverage policy with no gray area. The CMS vitamin B12 injection coverage policy under NCD 135 Medicare is unambiguous: these injections fail on two independent grounds, and neither one is a close call. The policy does not list specific CPT or HCPCS codes — but that doesn't reduce your exposure. Claims still get submitted, and claims still get denied.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS / Medicare |
| Policy | Vitamin B12 Injections to Strengthen Tendons, Ligaments, etc., of the Foot |
| Policy Code | NCD 135 |
| Change Type | Modified |
| Effective Date | 2026-03-07 |
| Impact Level | Medium — narrow service, but high denial rate if billed |
| Specialties Affected | Podiatry, orthopedics, physical medicine, primary care with foot complaint billing |
| Key Action | Flag and reject any charge capture for vitamin B12 injections billed for foot tendon or ligament strengthening before claims go out the door |
CMS Vitamin B12 Injection Coverage Criteria and Medical Necessity Requirements 2026
NCD 135 is a National Coverage Determination. That means this is a national-level Medicare rule — not a local coverage determination (LCD) set by a Medicare Administrative Contractor (MAC). It applies uniformly across all Medicare plans and all MACs.
The Centers for Medicare & Medicaid Services denies coverage for vitamin B12 injections used to strengthen tendons, ligaments, or other foot structures on two separate grounds. First, there is no clinical evidence that B12 injections strengthen weakened tendons or ligaments. Second, this service falls under the subluxation exclusion as a nonsurgical treatment.
Both reasons are independently disqualifying. Even if you believe one argument is weak, the other stands. CMS does not leave room for a medical necessity argument here.
What "Reasonable and Necessary" Means Here
Medicare covers services that are reasonable and necessary under §1862(a)(1) of the Social Security Act. CMS reviewed the evidence and concluded vitamin B12 injections for foot tendon and ligament strengthening don't meet that bar.
This matters because the reasonable and necessary standard is the foundation of every Medicare coverage decision. When CMS cites §1862(a)(1) in a denial rationale, that's a hard stop — not a documentation problem, not a coding problem. No amount of chart notes or prior authorization requests will fix it.
Prior authorization is not a path forward here either. There is no prior authorization process available for a service CMS has determined is not reasonable and necessary under a National Coverage Determination. You cannot pre-approve a non-covered service.
CMS Vitamin B12 Injection Exclusions and Non-Covered Indications
The entire clinical indication — vitamin B12 injections to strengthen tendons, ligaments, and related structures of the foot — is non-covered. There is no covered subset.
The subluxation exclusion compounds this. CMS classifies this as nonsurgical treatment under that exclusion. Podiatry billing teams should understand how the subluxation exclusion operates because it cuts across several foot-related services, not just B12 injections. If your practice bills a range of conservative foot care, your compliance officer should have a clear map of which services fall under that exclusion.
The policy cross-references the Medicare Benefit Policy Manual, Chapter 1 §30 and Chapter 16 §100. Pull those references if you need the full regulatory context for an internal audit or a payer dispute. Chapter 16 §100 specifically addresses the subluxation exclusion, and that's where the second leg of this denial lives.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Vitamin B12 injection to strengthen foot tendons and ligaments | Not Covered | No specific codes listed in NCD 135 | Fails medical necessity under §1862(a)(1); also excluded under subluxation provision as nonsurgical treatment |
| Vitamin B12 injection for any foot structure strengthening purpose | Not Covered | No specific codes listed in NCD 135 | Both grounds are independently disqualifying; no prior authorization pathway available |
CMS Vitamin B12 Injection Billing Guidelines and Action Items 2026
The effective date of March 7, 2026 means this modified policy is already active. If you haven't audited your charge capture for this service, do it now.
| # | Action Item |
|---|---|
| 1 | Audit your charge capture immediately. Search your system for any B12 injection billing associated with foot tendon or ligament indications. Pull claims from the past 90 days. If any went out after March 7, 2026, review them for denial risk and consider proactive correction before a RAC audit finds them first. |
| 2 | Update your encounter templates and order sets. If your podiatry or orthopedic providers have any order sets that include B12 injections for conservative foot care, remove or flag them. A provider ordering a non-covered service in good faith doesn't protect you from a claim denial — or worse, a recoupment. |
| 3 | Train front-line billing staff on the two-pronged denial rationale. When a denied claim comes back, your team needs to understand why a B12 injection appeal will fail. The denial is not a coding error. It's not a documentation gap. Appealing it as if it were wastes time and generates noise in your denial management workflow. |
| 4 | Do not bill expecting prior authorization to solve this. Some teams reflexively submit prior auth requests on borderline services. This is not borderline. Prior authorization does not apply to services excluded under an NCD. Save your team the administrative time. |
| 5 | Review the Medicare Benefit Policy Manual cross-references. Specifically, look at Chapter 1 §30 and Chapter 16 §100. If your practice has broader exposure to the subluxation exclusion — through other conservative foot care services — this is a good prompt to do a wider billing guidelines review. Talk to your compliance officer before the effective date implications compound across multiple service lines. |
| 6 | Document the patient communication process. If a patient requests this service and your provider believes it has clinical value, the right path is an Advance Beneficiary Notice of Noncoverage (ABN). The patient can then choose to receive the service and pay out of pocket. Without a properly executed ABN, your practice absorbs the cost. Make sure your front desk and billing team have the ABN workflow in place. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Vitamin B12 Foot Injections Under NCD 135
No Specific Codes Listed in NCD 135
The policy data for NCD 135 does not include specific CPT, HCPCS, or ICD-10 codes. This is not unusual for older NCDs — many were written before the current coding structure was fully standardized.
The absence of listed codes does not reduce your denial risk. CMS reviews claims based on the service description and the diagnosis code combination. A claim for a B12 injection with a foot tendon or ligament diagnosis will be subject to this NCD regardless of which injection administration code you used.
Practical Coding Guidance
Because no codes are specified in the NCD, your billing team should focus on the diagnosis and procedure combination rather than individual code lookups. Vitamin B12 injection billing for foot indications will draw scrutiny regardless of whether you bill an office injection administration code or a drug supply code.
If your practice also bills vitamin B12 injections for legitimate covered indications — such as documented B12 deficiency — make sure your documentation clearly supports the indication. A covered B12 injection claim with a foot complaint as the primary diagnosis is a red flag. Keep your diagnosis coding clean and tied to the actual reason for the injection.
Talk to your compliance officer if you have questions about how to separate covered B12 injection claims from non-covered foot-related claims in a mixed-indication scenario.
Why This Policy Modification Matters Beyond the Narrow Service
Here's the honest take: vitamin B12 injections for foot strengthening are not a high-volume service at most practices. This isn't a policy change that will reshape your revenue cycle.
But NCD 135 modifications are worth tracking for two reasons. First, any modification to an NCD signals that CMS reviewed the policy — which sometimes means related services get scrutinized too. The subluxation exclusion cross-reference in this policy is a signal to podiatry billing teams to audit the full scope of their conservative foot care billing. Second, small-volume services generate disproportionate audit exposure when they're billed incorrectly. A handful of non-covered claims for an injection CMS has explicitly excluded draws more scrutiny than a high-volume service with occasional documentation gaps.
The reimbursement issue here isn't rate-related — it's binary. These claims pay nothing. Every dollar billed for this service against Medicare is a dollar at risk of recoupment. Get it off your charge capture.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.